NCT05585996 is a Phase 1 clinical trial of CD19 CAR-T and CD19 CAR-DC in Relapsed and Refractory B-cell Lymphoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05585996?

NCT05585996 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT05585996?

Interventions in NCT05585996: CD19 CAR-T and CD19 CAR-DC.

What condition does NCT05585996 study?

NCT05585996 studies Relapsed and Refractory B-cell Lymphoma.

Is NCT05585996 still recruiting?

NCT05585996 is currently status unknown. Last updated 6 February 2023.

Last reviewed 2023-02-06 · How we verify

NCT05585996

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

Status unknown Phase 1 Last updated 6 February 2023

What this trial tests

Phase 1 trial testing CD19 CAR-T and CD19 CAR-DC in Relapsed and Refractory B-cell Lymphoma in 70 participants. Status unknown.

Timeline

1 August 2022

Primary endpoint
1 November 2025

30 December 2025

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	1 August 2022
Primary completion	1 November 2025
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

CD19 CAR-T and CD19 CAR-DC — full drug profile →

Conditions studied

Relapsed and Refractory B-cell Lymphoma — all drugs for Relapsed and Refractory B-cell Lymphoma →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 75, any sex, with Relapsed and Refractory B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open, single-arm, prospective, dose-escalation clinical trial designed to evaluate the safety and the preliminary efficacy of CD19-targeted CAR-T combined with CAR-DC in the treatment of relapsed and refractory B-cell lymphoma

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano RS, Vanmeerbeek I, Sprooten J, et al · · 2024 · cited 18× · PMID 39398476 · DOI 10.1080/2162402x.2024.2412876
Expanding the frontier of CAR therapy: comparative insights into CAR-T, CAR-NK, CAR-M, and CAR-DC approaches.
Zhang Y, Hu R, Xie X, Li Y. · · 2025 · cited 4× · PMID 40928667 · DOI 10.1007/s00277-025-06538-0
Innate immune cells in chimeric antigen receptor therapy.
Jassaud M, Ziane-Chaouche L, Duhamel M, Salzet M. · · 2026 · cited 1× · PMID 41058171 · DOI 10.1016/j.ymthe.2025.10.003
Spatiotemporal control of immunogenic cell death: rewiring tumor-immune dialogues for next-generation immunotherapy.
Li C, Zhu L, Wang Y, Zhao L, et al · · 2026 · PMID 41853278 · DOI 10.3389/fimmu.2026.1784935

Verify or expand the search:

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05585996 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 6 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05585996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing